memantine has been researched along with adamantane in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (20.00) | 18.2507 |
| 2000's | 2 (13.33) | 29.6817 |
| 2010's | 7 (46.67) | 24.3611 |
| 2020's | 3 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bormann, J; Hübers, M; Kornhuber, J; Riederer, P; Rusche, K | 1 |
| Kornhuber, J; Riederer, P; Schoppmeyer, K; Weller, M | 1 |
| Koshelev, S; Sobolevsky, A | 1 |
| Shah, RC | 1 |
| Lipton, SA | 1 |
| Lukomskaia, NIa; Magazanik, LG; Vataev, SI; Zhabko, EP | 1 |
| Gmiro, VE; Lukomskaia, NIa; Magazanik, LG; Oganesian, GA; Vataev, SI | 1 |
| Lukomskaia, NIa; Magazanik, LG; Oganesian, GA; Vataev, SI | 1 |
| Gmiro, VE; Serdyuk, SE; Veselkina, OS | 1 |
| Schaefer, HF | 1 |
| Gan'shina, TS; Gnedovskaya, EV; Kurza, EV; Maslennikov, DV; Mirzoyan, RS; Shabalina, AA; Tanashyan, MM | 1 |
| Henter, ID; Lepow, L; Luckenbaugh, DA; Park, L; Zarate, CA | 1 |
| Grieb, P; Rejdak, K | 1 |
| Brenner, SR | 1 |
| Kwon, DY; Park, MH | 1 |
2 review(s) available for memantine and adamantane
| Article | Year |
|---|---|
Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties.
Topics: Adamantane; Amantadine; Animals; Behavior, Animal; Dopamine; Electrophysiology; Hallucinogens; Humans; Memantine; Neuroprotective Agents; Receptors, N-Methyl-D-Aspartate; Substance-Related Disorders | 1994 |
Pathologically-activated therapeutics for neuroprotection: mechanism of NMDA receptor block by memantine and S-nitrosylation.
Topics: Adamantane; Alzheimer Disease; Animals; Dementia, Vascular; Humans; Memantine; Neuroprotective Agents; Nitric Acid; Receptors, N-Methyl-D-Aspartate | 2007 |
13 other study(ies) available for memantine and adamantane
| Article | Year |
|---|---|
Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study.
Topics: Adamantane; Amantadine; Binding Sites; Brain; Dizocilpine Maleate; Humans; Ion Channel Gating; Ion Channels; Kinetics; Memantine; Receptors, N-Methyl-D-Aspartate; Structure-Activity Relationship; Tritium | 1991 |
Two blocking sites of amino-adamantane derivatives in open N-methyl-D-aspartate channels.
Topics: Adamantane; Amantadine; Animals; Binding Sites; Cell Membrane; Cell Separation; Hippocampus; In Vitro Techniques; Kinetics; Memantine; Membrane Potentials; Models, Chemical; Models, Molecular; Patch-Clamp Techniques; Pyramidal Cells; Rats; Receptors, N-Methyl-D-Aspartate; Structure-Activity Relationship | 1998 |
Shift shown in influenza A adamantane resistance.
Topics: Adamantane; Alzheimer Disease; Antiviral Agents; Drug Resistance, Viral; Excitatory Amino Acid Antagonists; Humans; Influenza A virus; Influenza, Human; Memantine | 2006 |
[Effects of ionotropic glutamate receptor channel blockers on the development of audiogenic seizures in Krushinski-Molodkina rats].
Topics: Acoustic Stimulation; Adamantane; Animals; Cyclohexylamines; Diamines; Drug Administration Schedule; Epilepsy, Reflex; Excitatory Amino Acid Antagonists; Injections, Intramuscular; Male; Memantine; Motor Activity; Quaternary Ammonium Compounds; Rats; Receptors, AMPA; Receptors, Kainic Acid; Receptors, N-Methyl-D-Aspartate; Seizures | 2012 |
[Effects of ionotropic glutamate receptor channel blockers ON sleep-waking organization in rats].
Topics: Adamantane; Animals; Cyclohexylamines; Diamines; Epilepsy, Reflex; Excitatory Amino Acid Antagonists; Male; Memantine; Quaternary Ammonium Compounds; Rats; Rats, Wistar; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; Sleep | 2012 |
[The action of ionotropic glutamate receptor channel blockers on effects of sleep deprivation in rats].
Topics: Adamantane; Animals; Cyclohexylamines; Diamines; Electroencephalography; Injections, Intramuscular; Male; Memantine; Quaternary Ammonium Compounds; Rats; Rats, Transgenic; Rats, Wistar; Receptors, AMPA; Receptors, Kainic Acid; Receptors, N-Methyl-D-Aspartate; Sleep Deprivation; Sleep, REM; Wakefulness | 2013 |
Combined blockade of NMDA and AMPA receptors prevents acute kainate seizures and chronic kainate lethality in rats.
Topics: Adamantane; Amines; Animals; Anticonvulsants; Convulsants; Dose-Response Relationship, Drug; Excitatory Amino Acid Agonists; Injections, Intramuscular; Kainic Acid; Male; Memantine; N-Methylaspartate; Neuroprotective Agents; Pentylenetetrazole; Quinoxalines; Rats; Rats, Wistar; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; Seizures; Survival Analysis | 2014 |
Paul von Ragué Schleyer (1930-2014).
Topics: Adamantane; Chemistry; Dipeptides; Germany; History, 20th Century; Memantine; Nobel Prize; United States | 2015 |
[ANTIPLATELET AND ANTI-ISCHEMIC EFFECTS OF MEMANTINE AND 5-HYDROXYADAMANTAN-2-ONE IN PATIENTS WITH CEREBROVASCULAR PATHOLOGY AND IN EXPERIMENTS].
Topics: Adamantane; Adenosine Diphosphate; Aged; Animals; Animals, Outbred Strains; Blood Platelets; Cells, Cultured; Cerebral Cortex; Cerebrovascular Circulation; Epinephrine; Excitatory Amino Acid Antagonists; Female; Humans; Hypoxia-Ischemia, Brain; Ischemic Attack, Transient; Laser-Doppler Flowmetry; Male; Memantine; Middle Aged; Nimodipine; Platelet Aggregation; Rats; Vasodilator Agents | 2016 |
Case series: Antidepressant effects of low-affinity and low-trapping NMDA receptor antagonists did not predict response to ketamine in seven subjects.
Topics: Adamantane; Adult; Antidepressive Agents; Depression; Excitatory Amino Acid Antagonists; Female; Humans; Ketamine; Male; Memantine; Middle Aged; Niacinamide; Predictive Value of Tests; Psychiatric Status Rating Scales; Receptors, N-Methyl-D-Aspartate; Treatment Outcome | 2017 |
Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment.
Topics: Adamantane; Adult; Aged; Aged, 80 and over; Amantadine; Asymptomatic Infections; Betacoronavirus; Cognitive Dysfunction; Coronavirus Infections; COVID-19; Dopamine Agents; Female; Humans; Male; Memantine; Middle Aged; Multiple Sclerosis; Pandemics; Parkinson Disease; Pneumonia, Viral; Protective Factors; SARS-CoV-2; Severity of Illness Index | 2020 |
The potential of memantine and related adamantanes such as amantadine, to reduce the neurotoxic effects of COVID-19, including ARDS and to reduce viral replication through lysosomal effects.
Topics: Adamantane; Amantadine; COVID-19; Humans; Lysosomes; Memantine; Respiratory Distress Syndrome; Respiratory Insufficiency; SARS-CoV-2; Virus Replication | 2020 |
A retrospective review of memantine use and COVID-19-associated mortality from a national database.
Topics: Adamantane; COVID-19; Humans; Memantine; Retrospective Studies; SARS-CoV-2 | 2021 |